Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients

• Status: Completed
• Trial end date: 2014-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Use of Paricalcitol in stage Vd Chronic Kidney Disease patients, over the effect of inflammatory and oxidative stress parameters.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ricardo Mouzo Mirco
• Treatments: Atorvastatin; Atorvastatin Calcium; Ergocalciferols

Criteria

Inclusion Criteria:

• Vd CKD patients using haemodialysis during 3 or more months.

• Tunnelized-bearer permanent catheters on haemodialysis at last 6 months previous at the beginning of the study. .

• Kt stable, over 45 litres on both sexs.

• Patients in treatment wiht atorvastatin

• Patients without infectious or inflammatory processes over 8 weeks.

• Two consecutive PTH < than 400 pg/ml; Ca<10.2 and P <7.0 mg/dl.

Exclusion Criteria:

• Patients > 18 years.

• Pregnant women.

• Patients hospitalized 4 weeks before the beginning of the treatment.

• Immunosuppressor intake.